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presence or absence of non-specific lung lesions. However, there was not a sufficient body of research 
evaluating the same interventions and outcomes to allow a meaningful synthesis of the comparative 
efficacy of the vaccines. To build this body of research, additional rigor in trial design and analysis, and 
detailed reporting of trial methods and results are warranted. 
Keywords 
Antibiotic use, bacterial vaccines, network meta-analysis, respiratory disease, swine, systematic review 
Disciplines 
Large or Food Animal and Equine Medicine | Veterinary Microbiology and Immunobiology | Veterinary 
Preventive Medicine, Epidemiology, and Public Health 
Comments 
This article is published as Sargeant, Jan M., Dapeng Hu, Annette M. O’Connor, Chong Wang et al. 
"Efficacy of bacterial vaccines to prevent respiratory disease in swine: a systematic review and network 
meta-analysis." Animal Health Research Reviews 20, no. 2 (2019): 274-290. DOI: 10.1017/
S1466252319000173. Posted with permission. 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
Authors 
Jan M. Sargeant, Bhumika Deb, Michele D. Bergevin, Katheryn Churchill, Kaitlyn Dawkins, Jennifer Dunn, 
Dapeng Hu, Carly Moody, Annette M. O’Connor, Terri L. O’Sullivan, Mark Reist, Chong Wang, Barbara 
Wilhelm, and Charlotte B. Winder 





Cite this article: Sargeant JM et al (2019).
Efficacy of bacterial vaccines to prevent
respiratory disease in swine: a systematic
review and network meta-analysis. Animal
Health Research Reviews 20, 274–290. https://
doi.org/10.1017/S1466252319000173
Received: 21 June 2019
Revised: 19 November 2019
Accepted: 19 November 2019
Key words:
Antibiotic use; bacterial vaccines; network
meta-analysis; respiratory disease; swine;
systematic review
Author for correspondence:
Jan M. Sargeant, Department of Population
Medicine, Ontario Veterinary College,
University of Guelph, Guelph, Ontario, Canada.
E-mail: sargeanj@uoguelph.ca
© The Author(s), 2020. This is an Open Access
article, distributed under the terms of the
Creative Commons Attribution licence (http://
creativecommons.org/licenses/by/4.0/), which
permits unrestricted re-use, distribution, and
reproduction in any medium, provided the
original work is properly cited.
Efficacy of bacterial vaccines to prevent
respiratory disease in swine: a systematic
review and network meta-analysis
Jan M. Sargeant1,2 , Bhumika Deb1,2, Michele D. Bergevin1,2,
Katheryn Churchill1,2, Kaitlyn Dawkins1,2, Jennifer Dunn1,2, Dapeng Hu3,
Carly Moody1,2, Annette M. O’Connor4 , Terri L. O’Sullivan1, Mark Reist1,2,
Chong Wang3,4 , Barbara Wilhelm1,2 and Charlotte B. Winder1,2
1Department of Population Medicine, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada;
2Centre for Public Health and Zoonoses, University of Guelph, Guelph, ON, Canada; 3Department of Statistics,
Iowa State University, Ames, Iowa, USA and 4Department of Veterinary Diagnostic and Production Animal
Medicine, Iowa State University College of Veterinary Medicine, Ames, Iowa, USA
Abstract
A systematic review and network meta-analysis (MA) was conducted to address the question,
‘What is the efficacy of bacterial vaccines to prevent respiratory disease in swine?’ Four elec-
tronic databases and the grey literature were searched to identify clinical trials in healthy swine
where at least one intervention arm was a commercially available vaccine for one or more
bacterial pathogens associated with respiratory disease in swine, including Mycoplasma hyop-
neumoniae, Actinobacillus pleuropneumonia, Actinobacillus suis, Bordetella bronchiseptica,
Pasteurella multocida, Stretococcus suis, Haemophils parasuis, and Mycoplasma hyorhinis.
To be eligible, trials had to measure at least one of the following outcomes: incidence of clin-
ical morbidity, mortality, lung lesions, or total antibiotic use. There were 179 eligible trials
identified in 146 publications. Network MA was undertaken for morbidity, mortality, and the
presence or absence of non-specific lung lesions. However, there was not a sufficient body of
research evaluating the same interventions and outcomes to allow a meaningful synthesis of
the comparative efficacy of the vaccines. To build this body of research, additional rigor in
trial design and analysis, and detailed reporting of trial methods and results are warranted.
Introduction
Porcine respiratory disease complex (PRDC), which refers to respiratory disease caused by
viruses or bacteria in swine, is the leading single cause of death during the nursery stage
(47.3%), and is responsible for the majority of swine deaths during the grower–finisher produc-
tion stage (75.1%) (USDA, 2016a). Swine respiratory disease is multifactorial, involving the
interplay between environmental factors, host characteristics, and infectious disease agents
(Opriessnig et al., 2011). Bacterial pathogens involved in respiratory disease may induce disease,
or act as co-infections, making the animal more susceptible to other disease agents (Opriessnig
et al., 2011). Bacterial pathogens frequently involved in PRDC include Actinobacillus pleuro-
pneumonia, Actinobacillus suis, Bordetella bronpchiseptica, and Mycoplasma hyopneumoniae
(Opriessnig et al., 2011; VanAlstine, 2012). Treatment of respiratory disease is a major source
of antimicrobial use in swine production (Karriker et al., 2012). In the USA in 2012, the
National Animal Health Monitoring System (NAHMS), which is run by the United States
Department of Agriculture (USDA), reported that 59.9% of swine farm nursery sites used
injectable antibiotics and 41.2% used water-soluble antibiotics to treat respiratory disease.
Similarly, the NAHMS reported that 72.8% of swine farm grower–finisher sites used injectable
antibiotics and 64.2% used water-soluble antibiotics to treat respiratory disease (USDA, 2016b).
Antibiotic use in animals or humans leads to the development of antimicrobial resistance
(AMR). The World Health Organization (WHO) Global Action Plan on Antibiotic Resistance
(2015) stated that AMR is currently one of the most critical threats to global health, food
security, and economic development. To minimize the development of AMR, it is therefore
essential that antibiotics be used judiciously in both animal and human medicine. The
American Association of Swine Veterinarians (AASV) endorsed a position statement regard-
ing the judicious use of antimicrobials in swine production that encourages veterinarians to
implement preventive strategies (AASV, 2019). One such approach is the use of vaccinations,
intended to prevent disease and therefore the use of antibiotics to treat clinical illness. Swine
veterinarians and producers require information on the effectiveness of alternative non-
antibiotic treatments, such as vaccinations, to mitigate the impact
of major bacterial pathogens involved in swine respiratory disease
without relying on antibiotics.
The systematic review method has been recognized for decades
as a transparent and replicable method for synthesizing and asses-
sing the available evidence on the effectiveness of interventions
(Higgins and Green, 2011). The use of systematic review methods
to synthesize scientific data for use in policy-making has been
endorsed internationally by the WHO, the European Food Safety
Authority (EFSA), and the Codex Alimentarius Commission
(CAC) (EFSA, 2010; CAC, 2014; WHO, 2018). Meta-analysis
(MA), or the statistical pooling of estimates of intervention effect
sizes across individual studies, may also be combined with system-
atic review to provide a summary estimate of intervention efficacy
(Higgins and Green, 2011). However, one important limitation of a
standard (pairwise) MA is that it only allows the comparison of
pairs of treatments, such as a specific vaccine to a placebo or the
comparison of two vaccines.
Often veterinarians and producers are faced with multiple pos-
sible treatment options, and thus they require comparisons of rela-
tive efficacy between more than two alternatives. A network
meta-analysis (NMA) generates estimates of the relative efficacy of
multiple interventions by incorporating direct head-to-head com-
parisons of interventions based on the available literature, as well
as indirect comparisons of interventions across a network of trials
(Dias et al., 2011; Cipriani et al., 2013). For example, if treatment
A is compared to treatment B in one or more studies, and treatment
B is compared to treatment C in one or more studies, the relative
relationship between treatments A and C can be inferred indirectly
from the available information under some standard assumptions.
Thus, given a dataset of studies investigating the efficacy of interven-
tion options for the same outcome, within which the underlying
NMA model assumptions are met, NMA allows the comparison
of multiple interventions using direct and indirect evidence (Lu
and Aedes, 2004). A systematic review followed by an NMA there-
fore provides a rigorous method for synthesizing evidence regarding
the relative effectiveness of available swine respiratory vaccines.
The objective of this study was to conduct a systematic review
and NMA to address the question: ‘What is the relative efficacy of
commercially produced bacterial vaccines to prevent respiratory
disease in swine from controlled trials with natural disease exposure?’.
Methods
Protocol
A review protocol was prepared a priori, and was reported in
accordance with the PRISMA-P guidelines (Moher et al., 2015).
The protocol was published in the University of Guelph’s institu-
tional repository (https://atrium.lib.uoguelph.ca/xmlui/handle/
10214/10046). The protocol is also available through Systematic
Reviews for Animals and Food (SYREAF) (http://www.syreaf.
org/contact/). The Preferred Reporting Items for Systematic
Reviews and Meta-Analyses extension for NMA (PRISMA –
NMA) guidelines were used for the reporting of this systematic
review (Hutton et al., 2015).
Eligibility criteria
Primary research studies available in English were eligible for
inclusion in the review. In addition, primary studies must have
included the following elements based on the PICOS components:
Population (P): Healthy swine at any stage of production;
Intervention (I): At least one intervention arm was a commercially
available vaccine or a commercially produced injectable
autogenous vaccine (derived from culture) for bacterial patho-
gens associated with respiratory disease in swine, specifically
M. hyopneumoniae, A. pleuropneumonia, A. suis, Bordetella
bronchiseptica, Pasteurella multocida, Stretococcus suis,
Haemophils parasuis, and Mycoplasma hyorhinis;
Comparator (C): Negative control group, sham treatment, saline pla-
cebo, or other alternative treatment (including another vaccine);
Outcomes (O): At least one of the following outcomes was evalu-
ated: morbidity (clinical morbidity as defined by the authors,
cough index, or general or specific lung lesions), mortality, or
total antibiotic use; and
Study design (S): Controlled trials with natural disease exposure.
Information sources
Five electronic databases were searched in order to identify primary
research studies that met the eligibility criteria: AGRICOLA (via
ProQuest, from 1970), CAB Direct (via Web of Science, from
1910), MEDLINE (via PubMed, from 1946), Conference
Proceedings Citation Index – Science (via Web of Science, from
1990), and Science Citation Index (via Web of Science, from
1900). No further date restrictions were placed, and the searches
were not limited by language, study design, or publication type.
In addition, a single reviewer hand-searched the table of contents
of the following conferences: Proceedings from the American
Association of Swine Veterinarians (1999–2018), the American
Association of Swine Veterinarians Pre-Conference Seminars
(2007–2018), and the International Pig Veterinary Society
Congress (2000–2018). No attempt was made to contact study
authors for additional information pertaining to their study.
Search
The search strategy was comprised of four distinct concepts:
swine at any stage of production, vaccines, bacteria associated
with respiratory disease in swine, and respiratory outcomes. A
list of relevant search terms was compiled for each concept within
the search strategy. Search terms for each part of the strategy were
combined using the Boolean operator ‘OR’, and parts were linked
using the Boolean operator ‘AND’. The full search strategy as
developed for Science Citation Index is listed in Table 1. The
search strings were modified as necessary to meet the formatting
requirements of each of the remaining databases. Database
searches were conducted on 20 August 2018 via the library
resources at the University of Guelph, Canada. Search results
were uploaded to EndNoteX7 (Clarivate Analytics, Philadelphia,
PA, USA) and duplicate results were identified and removed.
Records were then uploaded to the systematic review management
software DistillerSR (Evidence Partners Inc., Ottawa, ON, USA)
and additionally examined for duplicate records. If the same
data were published in a conference proceeding and a journal art-
icle, the journal article was used and the conference proceedings
were labelled as a duplicate and excluded.
Study selection
DistillerSR (Evidence Partners®) was used for all screening, data
extraction, and risk of bias assessments. Two independent
reviewers initially screened all of the titles and abstracts captured
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by the search for potential eligibility. All reviewers conducted a
pre-test of the first 250 titles and abstracts to ensure clarity of
understanding and consistent application of the questions.
Thereafter, the following questions were used to assess eligibility:
(1) Is this a primary study that evaluated the use of vaccines for
bacterial causes of respiratory disease in live swine? YES, NO
(exclude), UNCLEAR
(2) Is there a concurrent comparison group (i.e. controlled trial
with natural or deliberate disease exposure, or analytical
observational study)? YES, NO (exclude), UNCLEAR
(3) Is the text available in English? YES (include for full-text screen-
ing), NO (exclude), UNCLEAR (include for full-text screening)
Citations were excluded if both reviewers responded ‘NO’ to
any of the questions; agreement was at the include/exclude
level. Disagreements were resolved by consensus or by a third
reviewer (JMS or CBW) if consensus could not be reached. Full
texts were acquired for citations that passed the initial eligibility
screening or for which the results were unclear. Two independent
reviewers conducted the full-text screening, using the first 10 arti-
cles as a pre-test. The following questions were used to evaluate
the eligibility of the full-text articles:
(1) Is the full text available with >500 words? YES, NO (EXCLUDE)
(2) Is the full text available in English? YES, NO (EXCLUDE)
(3) Does this study assess the use of a monovalent or polyvalent
commercially available vaccine or a commercially produced
injectable autogenous vaccine (derived from culture) for one
or more of the following bacterial pathogens associated
with respiratory disease in swine:Mycoplasma hyopneumoniae,
Actinobacillus pleuropneumoniae, Actinobacillus suis,
Bordetella bronchiseptica, Pasteurella multocida, Streptococcus
suis, Haemophilus parasuis, or Mycoplasma hyorhinis? YES,
NO (EXCLUDE)
(4) Is there a concurrent comparison group? (i.e. controlled trial
with natural or deliberate disease exposure, or analytical
observational study)? YES, NO (EXCLUDE)
(5) Are at least one of the following outcomes described: clinical
morbidity (as defined by the authors), cough index, lung
lesions at slaughter, mortality, or antibiotic use? YES, NO
(EXCLUDE)
(6) Is the study a controlled trial with natural disease exposure?
YES (moves to data extraction stage),
NO, the study is a controlled trial with deliberate disease
induction (indicate the pathogen targets included in the
vaccine, but exclude from data extraction)
NO, the study is an observational study (indicate the patho-
gen targets included in the vaccine but exclude, from
data extraction)
Studies were included in the NMA if sufficient data were reported
to enable the calculation of the log odds ratio (OR) and the stand-
ard error of the log OR, based on the extraction of the prioritized
outcome metrics. The criteria for inclusion in the NMA are
described in the statistical analysis section.
Data collection
Two reviewers used a standardized form to independently extract
data from all citations meeting the full-text screening criteria. The
data extraction form was created using a hierarchical nesting of
forms in DistillerSR, which allowed data from multiple compari-
sons or from multiple outcomes to be linked. The forms were pre-
tested on the first 10 articles by all reviewers to ensure consistency
and for training in the use of nested forms. Discrepancies in data
extraction were resolved by consensus, with mediation by JMS
and CBW if an agreement could not be reached.
Data items
Study characteristics
Extracted study characteristics included country of conduct,
year(s) the study was conducted, months of data collection,
whether the study was a commercial or research trial, the number
of herds/farms enrolled in the study, the reason for vaccinating
(endemic disease, prevention of clinical disease, response to a dis-
ease outbreak, or not reported), farm- and animal-level inclusion/
exclusion criteria, and whether the study reported clinically ill
animals at the time the intervention was given.
Interventions
Details on each intervention arm included vaccine name, the
target bacterium or bacteria for the vaccine, other infectious dis-
ease targets included in the vaccine, dose, route, frequency of
administration, the stage of production at which the intervention
was administered and at which the outcome was measured, the
type of vaccine (killed, modified live, autogenous, or not
reported), and whether there were any concurrent treatments.
A description of other intervention arms (e.g. a non-eligible vac-
cine, placebo, or alternative treatment) also was extracted, as well
as the number of animals and pens enrolled and analyzed in
each treatment group. Information was collected on whether
animals in different intervention groups were comingled within
pens or whether each pen only contained animals in the same
intervention group.
Eligible outcomes
Outcomes eligible for inclusion were morbidity (clinical morbid-
ity defined by the authors as observed illness or illness requiring
treatment, cough index, and general and specific lung lesions),
Table 1. Full electronic search strategy used to identify trials evaluating the comparative efficacy of vaccines against bacteria associated with respiratory disease in
swine, formatted for Science Citation Index (Web of Science), conducted on 20 August 2018
#1 TS = (swine OR pig* OR piglet* OR gilt* OR boar* OR sow* OR hog* OR weane* OR porcine NOT guinea) 878,151
#2 TS = (vaccine OR vaccination OR bacterin) 287,366
#3 TS = (hyopneumoniae OR Mycoplasma OR Actinobacillus OR ‘atrophic rhinitis’ OR suis OR Bordetella OR bronchiseptica OR Pasteurella
OR Pasteurellosis OR multocida OR Streptococcus OR Haemophilus OR Glasser’s OR Glassers OR parasuis OR hyorhinis)
160,015
#4 TS = (pneumonia OR pleuritis OR pleuropneumonia OR pleuropneumoniae OR respiratory OR SRD) 492,637
#5 #4 AND #3 AND #2 AND #1 755
276 Jan M. Sargeant et al.
mortality, and total antibiotic use. Morbidity related to respiratory
disease was included as a critical outcome in the review protocol,
whereas lung lesions were not included as an eligible outcome in
the protocol. However, as most studies included lung lesions as a
proxy for morbidity (clinical or subclinical), we added this out-
come beginning at the title and abstract screening level as a proto-
col modification. For trials in which there were some animals with
the clinical disease at the start of the study, data were only
extracted for incident cases (i.e. data were only extracted when
they were reported separately for the animals that did not have
clinical disease at the start of the trial).
Multiple specific outcomes within the same outcome category
often were reported for both morbidity and lung lesions. In these
instances, a single outcome within each category was extracted
based on priorities identified at the start of the data extraction
process. For morbidity, if both general and respiratory-related
were reported within the same trial, respiratory-related morbidity
data were extracted. For lung lesions, information on general lung
lesions (i.e. not specific to a pathogen) was extracted when pre-
sented. If an article also included disease-specific lung lesions, a
single measure for disease-specific lesions was extracted; the pri-
oritization (based on author description) was as follows:
(1) Lung lesions consistent with enzootic pneumonia or
Mycoplasma spp.;
(2) Lung lesions consistent with Actinobaccillus pleuropneumonia
(APP), including APP index;
(3) Slaughterhouse pleurisy evaluation system (SPES) scores; and
(4) Pathology described as pleuritic or pleurisy.
When extracting data on effects and effect sizes, relative effect
measures (OR, risk ratio (RR), or mean difference) and corre-
sponding precision estimates were extracted when these data
were provided. Information on any additional adjusted variables
used in the calculation of effect sizes was also extracted, as were
losses to follow-up. When relative effect measures were not
reported, arm-level data were extracted, including variance mea-
sures for continuous data. If a measure of variance was not
reported, or could not be calculated from the available informa-
tion, data for that comparison were not extracted. When results
were presented only in a graph, with no numerical labels, data
were not extracted. When data were reported as a frequency of
observations within ordinal categories (e.g. for lung lesions, data
in some trials were reported as the number of pigs with a score
of 0, the number of pigs with a score between 1 and 20, the num-
ber of pigs with a score between 21 and 40, etc.), the data were
collapsed into a binary outcome for data extraction (e.g. lung
lesions were present or not present).
Some publications included multiple trials, or trials in multiple
herds where the results were reported separately by the herd. In
both of these instances, the results were extracted separately and
are reported as separate trials.
Geometry of the network
We used a visual approach to qualitatively evaluate the geometry
of the network, to determine if some pairwise comparisons domi-
nated and to determine whether the network appeared to have a
star or web-like structure. We also evaluated whether there were
intervention comparisons that were not linked to the network
(i.e. did not have an intervention in common with one or more
other published studies).
Risk of bias in individual studies
Risk of bias was assessed at the outcome level for the three main
outcomes for trials included in the NMAs using the Cochrane
risk-of-bias tool for randomized trials (RoB 2.0). This tool provides
a framework for assessing the likelihood that bias could be intro-
duced in each of the five domains. Specifically, the risk of bias
domains included in the tool are: risk of bias arising from the ran-
domization process; risk of bias due to deviations from the
intended intervention(s); risk of bias due to missing outcome
data; risk of bias in the measurement of the outcome; and risk of
bias in the selection of the reported result (Higgins et al., 2016).
All outcomes included in an NMA were evaluated using this
tool, regardless of whether interventions were allocated at the
individual or pen level, or whether animals within intervention
groups were comingled or grouped by intervention within pens.
Signaling questions are a component of the RoB 2.0 tool that is
used to elicit information on the use of trial features that are rele-
vant to the potential for bias in a trial. The signaling questions
were modified to address common practices in livestock health
for animals that are grouped in pens. For assessing risk of bias
due to allocation, the Cochrane risk of bias tool includes a ques-
tion on whether the authors described the method for generating
the random allocation sequence. This question was modified to
include a response for studies where allocation to intervention
group(s) was reported as ‘random’, but no information was pro-
vided on the actual method for generating the random sequence.
In the RoB 2.0 domain related to deviations from the intended
intervention, there is a question on whether participants were
aware of their intervention group allocations; for each of the stud-
ies in this review, this question was answered as a ‘no’ because the
participants in these trials were pigs. An additional question in
this domain asks about blinding of study personnel, and for the
purposes of this review, this question was clarified to refer to
the blinding of animal caregivers.
The overall risk of bias within each domain was calculated
based on the algorithms suggested by Higgins et al. (2016),
with the exception of the domain related to randomization. For
this domain, allocation concealment was not considered as a cri-
terion related to bias due to the randomization process, as all eli-
gible pens and animals are included in swine trials. Furthermore,
it is unlikely that a producer or investigator would have any
treatment preference for a given pen, as the differential economic
value of animals or pens would not be known at the time
interventions are allocated. This approach is consistent with
the risk of bias assessments of other livestock studies (Moura
et al., 2019).
Summary measures
The summary effect size was the log OR, which was converted
back to the RR using the baseline risk and a Bayesian approach
method of estimation. For the morbidity outcome, the posterior
mean and standard deviation of the baseline risk mean were
−2.2448 and 1.4449 and the posterior mean and standard devi-
ation of the baseline risk standard deviation were 1.3853 and
0.2455. For the mortality outcome, the posterior mean and stand-
ard deviation of the baseline risk mean were −2.7471 and 0.7528
and the posterior mean and standard deviation of the baseline risk
standard deviation were 0.7437 and 0.0779. For the lung lesion
outcome, the posterior mean and standard deviation of the base-
line risk mean were 1.378 and 1.7094, and the posterior mean and
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standard deviation of the baseline risk standard deviation were
1.6433 and 0.2941.
For studies that had zero cells for some data points, the ORs
could not be calculated. Such trials were therefore excluded
from the analyses.
Planned methods of analysis
After data extraction was complete, a treatment map of all reported
interventions was compiled (Table 2). Vaccines for the same bac-
terial target produced by different companies were considered to
be different interventions, because the specific bacterial or viral
strains used in the manufacture of the vaccine may differ, or the
products may contain different antigens or adjuvants. However,
if the same vaccine or intervention arm was issued via different
routes or in a different number of doses, then this was considered
to be the same intervention. Vaccines with identical bacterial tar-
gets that were produced in different countries by the same com-
pany were also considered to be part of the same intervention
arm. Vaccines that incorporated an additional treatment, such as
an immune stimulant, were considered to be separate interventions
from those vaccines that did not include the additional treatment.
Vaccines containing only viral respiratory targets, non-commercial
vaccines, or other identified interventions were included as com-
parison arms in the MA, but because these were not the focus of
this review, they are not shown in the ranked results.
Some studies provided separate morbidity results for more
than one stage of production. In order to conduct the NMA,
only one set of results was included per trial. To identify the
most relevant set of results for each trial, we first prioritized over-
all results representing the entire production process, followed by
results from the grower/finisher stage, followed by results from the
nursery stage. The grower phase was prioritized over the nursery
phase as most vaccines were given on entry to the nursery and
would be expected to take some period of time before immuno-
logical protection could be achieved.
The methodological approach for conducting network
meta-analyses has been described in detail elsewhere (Dias
et al., 2011; O’Connor et al., 2013). For all studies included in
the review, results were converted into log ORs for the present
analysis. If the authors reported a RR, this was converted into a
log OR using the reported risk of disease in the placebo group.
When authors reported the probability of an outcome in each
intervention group based on a statistical model, that probability
was converted to a log OR using a process described elsewhere
(Hu et al., 2019).
Selection of prior distributions in Bayesian analysis
The choice of prior probability distributions was based on an
approach reported previously (Dias et al., 2011). Accordingly,
we assessed both σ ∼ U (0,2) and σ ∼ U (0,5). The results sug-
gested that σ ∼ U (0,5) was preferred, and so we retained this
prior in the model.
Implementation and output
All posterior samples were generated using Markov Chain Monte
Carlo (MCMC) simulation, which was implemented using Just
Another Gibbs Sampler (JAGS) software (Plummer 2015). All
statistical analyses were performed using R software (version
3.5.2) (RCore, 2015). The model was fitted using JAGS; JAGS
was called from R via the rjags package (version 4-8)
(Plummer, 2015). Three chains were simulated in the analysis,
and convergence was assessed using Gelman–Rubin diagnostics.
We discarded 5000 ‘burn-in’ model iterations and based all infer-
ences on a further 10,000 model iterations. The model output
included all possible pairwise comparisons using log ORs (for
inconsistency assessment), RRs (for comparative efficacy report-
ing), and the treatment failure rankings (for comparative efficacy
reporting).
Assessment of model fit
To assess the fit of the model, we examined the residual deviance
between the predicted values of the log ORs from the NMA model
and the observed value for each study (Dias et al., 2010).
Assessment of inconsistency
NMA relies on an assumption of consistency between direct and
indirect intervention effects, apart from the usual variation that
stems from a random-effects MA model (White et al., 2012). For
example, if one trial compares the direct effect of a treatment A
with the effect of treatment B, and another study compares the effi-
cacy of treatments B and C, then the effect of A relative to B and B
relative to C can be used to infer the (indirect) effect of A relative to
C. The assessment of inconsistency compares whether the direct
effects and the indirect effects give a similar result. We used the
back-calculation method to assess the consistency assumption in
our NMA (Dias et al., 2010). We compared the estimates from
the direct and indirect models and considered the standard devi-
ation of each estimate, rather than relying on the P-values.
Risk of bias across studies (across the network)
To describe the quality of the evidence network, a modification of
the Grading of Recommendation Assessment, Development and
Evaluation (GRADE) approach for NMA was used (Salanti
et al., 2014; Papakonstantinou et al., 2018). The GRADE frame-
work provides a method of evaluating the quality or certainty of
evidence and the strength of the recommendations derived from
that evidence. The GRADE for NMA was conducted using the
Confidence in Network Meta-Analysis (CINeMA) online software
(http://cinema.ispm.ch). CINeMA calculates intervention effects
using a frequentist approach, which is based on the metafor pack-
age in R (Viechtbauer, 2010). The contribution matrix of direct
and indirect evidence for the risk of bias was based on this ana-
lysis. The GRADE approach in CINeMA examines six different
domains: within-study bias, across-studies bias, indirectness,
imprecision, heterogeneity, and incoherence.
Rather than presenting indirectness and overall within-study
bias, we replaced these domains with an evaluation of the contri-
bution of studies based on their reporting of randomization and
blinding. We believed that randomization and blinding would
be more variable across studies compared to overall bias risk,
and would therefore be more informative. In a GRADE assess-
ment for NMA, indirectness refers to the differences between
the populations, interventions, and outcomes in the included
studies and the populations, interventions, and outcomes that
were the target of the NMA (Salanti et al., 2014). We felt that
all of the trials included in our NMA would have minimal indir-
ectness because the review was restricted to relevant populations.
We recognize that the swine population varies in regards to man-
agement, herd health practices, and prevalent pathogens.
However, these data may not be consistently reported in trial
reports, and attempting to extract this information was therefore
beyond the scope of this review.
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Table 2. Eligible vaccines targeting bacteria associated with respiratory disease in swine identified for this systematic review
Code Product name Manufacturer Disease agent targets
CO Coglapix Ceva Santé Animale Actinobacillus pleuropneumoniae
COCI Coglapix and CircoFlex Ceva Santé Animale and
Boehringer Ingelheim
Actinobacillus pleuropneumoniae and PCV2
COTC Coglapix with antibiotics Tiamulin and
Colestin
Ceva Santé Animale Actinobacillus pleuropneumoniae
FL Ingelvac 3Flex Boehri nger-Ingelheim PCV2, Mycoplasma hyopneumoniae, PRRS
FLCL Flexcombo Boehringer Ingelheim PCV2, Mycoplasma hyopneumoniae
HD Himmvac Donoban-10 KBNP Inc. Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae,
Bordetella bronchiseptica, Pasteurella multocida, Streptococcus
suis, Haemophilus parasuis
HPC Hyogen, with PRRS and PCV2 vaccines Ceva Santé Animale Mycoplasma hyopneumoniae and PRRS, PCV2
HR Hyoresp Boehringer Ingelheim Mycoplasma hyopneumoniae
HY Hyogen Ceva Santé Animale Mycoplasma hyopneumoniae
IA Ingelvac APPX Boehringer Ingelheim Actinobacillus pleuropneumoniae
IAC Ingelvac APPX and CircoFlex Boehringer Ingelheim Actinobacillus pleuropneumoniae and PCV2
IH Inglevac HP-1 Boehringer Ingelheim Haemophilus parasuis
IM Ingelvac M Hyo, MycoFLEX Boehringer Ingelheim Mycoplasma hyopneumoniae
MP M + PAC, Mycopac MSD Animal Health Mycoplasma hyopneumoniae
MS Myprovac Suis Hipra Mycoplasma hyopneumoniae
MY Mycobuster Scientific Feed Laboratory Mycoplasma hyopneumoniae
MYC MycoFLEX Boehringer Ingelheim Mycoplasma hyopneumoniae
NAC Placebo, sham, or no treatment
PA Parasail Newport Laboratories Haemophilus parasuis
PAP Porcilis APP MSD Animal Health Actinobacillus pleuropneumoniae
PAT Porcilis APP with antibiotic Tiamulin MSD Animal Health Actinobacillus pleuropneumoniae
PC Porcilis PCV M Hyo MSD Animal Health Mycoplasma hyopneumoniae
PG Porcilis Glasser MSD Animal Health Haemophilus parasuis
PGP Porcilis Glasser and Porcilis PRRS MSD Animal Health Haemophilus parasuis and PRRS
PL Pleurinord MSD Animal Health Actinobacillus pleuropneumoniae
PN Pneuroguard Pfizer Actinobacillus pleuropneumoniae
PO Porcilis M Hyo, Porcilis M Hyo ID ONCE,
Porcilis Myco Silencer, Porcillis M1
MSD Animal Health Mycoplasma hyopneumoniae
POP Porcillis M hyo and PRRS vaccine MSD Animal Health Mycoplasma hyopneumoniae and PRRS
RE Respisure One, Respisure Zoetis Mycoplasma hyopneumoniae
REI Respisure plus immune stimulant Zoetis Mycoplasma hyopneumoniae
REL Respisure plus antibiotic lincomycin Zoetis Mycoplasma hyopneumoniae
REP Respisure plus PCV vaccine Zoetis Mycoplasma hyopneumoniae
RET Respisure plus antibiotic Tiamulin Zoetis Mycoplasma hyopneumoniae
SM Suvaxyn Respifend MH /Suvaxyn
Respifend APP
Zoetis Mycoplasma hyopneumoniae / Actinobacillus pleuropneumoniae
SP Sprintvac Merial Mycoplasma hyopneumoniae
ST Stellamune mono injection, Stellamune
mycoplasma, Stellamune Once
Elanco Mycoplasma hyopneumoniae
STL Stellamune plus antibiotic lincomycin Elanco Mycoplasma hyopneumoniae
STPC Stellamune plus PCV vaccine Elanco Mycoplasma hyopneumoniae
(Continued )
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To characterize randomization as reported in each of the
included studies, we sorted each trial into one of three categories:
(1) the authors reported random allocation to intervention group
(s) and provided information on the random sequence generation
(low risk); (2) the authors reported random allocation to interven-
tion group(s) without providing information on how the sequence
was generated (some concerns); and (3) the allocation method
was non-random or no information on the method of allocation
was provided (high risk). For blinding, we categorized the trials
based on reporting of the following: (1) outcome assessors and
caregivers were both blinded (low risk); (2) either outcome asses-
sors or caregivers were blinded (some concerns); and (3) neither
outcome assessor nor caregivers were blinded or no information
was provided (high risk).
The process for assessing across-studies bias in an NMA is not
well developed. Further, no pairwise comparisons in this review
included more than 10 trials, which is the number typically believed
to be necessary for an accurate across-studies bias assessment (Sterne
et al., 2000). Therefore, across-studies bias was not evaluated.
The imprecision assessment portion of the GRADE analysis
examines whether the boundaries of the confidence intervals for
the intervention effect indicate a clinically appreciable benefit or
harm, or whether the intervention effects are clinically ambiguous
(i.e. the confidence intervals span values representing both benefits
and harms, or benefit or harm and a null value). For this analysis,
we used an OR cut-point of 0.8 to represent a clinically meaningful
OR (i.e. an OR<0.8 represents appreciable benefit and an OR>1.25
represents appreciable harm). For an NMA, the major impact of
heterogeneity is whether it will affect decision-making; heterogen-
eity is thereby judged by the variability in effects in relation to a
clinically important effect size. Thus, ORs of 0.8 and 1.25 also
were also used in the assessment of heterogeneity. We did not pre-
sent the results of the incoherence analysis from CINeMA, which
measures the consistency of the network, because we conducted
and presented the consistency analysis results based on the
Bayesian analysis described previously in the Methods section.
Additional analyses
No additional analyses were conducted.
Results
Study selection
The database and grey literature searches identified 2157 unique
citations, 1621 of which were excluded at the title/abstract eligibil-
ity screening stage, and an additional 390 were excluded at full-
text screening (Fig. 1). The excluded citations included 81
challenge trials and eight observational studies that evaluated bac-
terial vaccines in swine and examined at least one eligible out-
come. Following the full-text screening, there were 179 trials
from 146 publications eligible for data extraction.
Study characteristics
The 179 trials were conducted in 29 countries; the most com-
monly reported country was France (N = 19/179; 10.6%), followed
by Belgium (N = 11/179; 6.1%). The country in which the trial
was conducted was not reported for 37/179 (20.7%) trials. The
year when the trial was conducted was not reported in most stud-
ies (155/179; 86.6%). Trials in which the year was reported were
conducted between 1981 and 2013. The majority (165/179;
92.2%) of the trials were conducted on commercial farms, with
the remainder either conducted in research herds (6/179; 3.4%)
or in an unreported setting (8/179; 4.5%). Trials were conducted
on a single farm for 132/179 (76.7%) of the trials, with the num-
ber of farms within a trial ranging from 1 to 16. The number of
farms enrolled in the trial was not reported in 7/179 trials
(3.9%). There were two key reasons for vaccinating reported in
the trials: the presence of endemic disease (155/179; 69.8%), or
the prevention of clinical disease (38/179; 21.2%). Vaccinating
because of a disease outbreak was not reported for any trial,
and the reason for vaccinating was not reported in 16/179 trials
(8.9%). Full details on the characteristics of the 179 trials that
were included in the review are available in Supplementary file
Table S1.
Complete outcome data could not be extracted from 44 trials
because insufficient information was reported in the study; rea-
sons included continuous outcomes reported as means without
a measure of variability, results presented only in figures, and pro-
portions provided without stating a denominator. As a result, data
for the NMA were extracted from only 135 trials. Of the 135 trials
for which data could be extracted, 26 included pens containing
pigs receiving different treatments, pigs receiving different treat-
ments were not co-mingled within pens in 30 trials, and it was
not possible to determine whether treatments were co-mingled
within pens in 79 trials.
Due to the large number of studies and outcomes, the remain-
der of the results focus on the three most common outcomes:
clinical morbidity, mortality, and the presence or absence of non-
specific lung lesions. In addition, cough index and total antibiotic
use were each measured in three trials.
Risk of bias within studies by outcome
Risk of bias within each of the studies included in the NMA was
determined using the Cochrane risk of bias domains for each of
Table 2. (Continued.)
Code Product name Manufacturer Disease agent targets
SU Suvaxyn M hyo mono, Suvaxyn M hyo,
Suvaxyn HM One
Zoetis Mycoplasma hyopneumoniae
SUL Suvaxyn M hyo plus antibiotic lincomycin Zoetis Mycoplasma hyopneumoniae
TH ThoroVax Vet Merck Mycoplasma hyopneumoniae
VM Vaxsafe MHP Avimex Mycoplasma hyopneumoniae
Other interventions that were not eligible for inclusion in the review, but were included as comparison groups (code): CircoFlex (CF), Porcilis PRRS (PP), Micotil (M), Tiamulin (T), Lincomycin
(L), Any immunostimulant (I), Florphenicol and amoxicillin (FA), J5 vaccine (J5).
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the three outcomes for which NMA were conducted. The results
are available in the Supplementary material Figs S1–3. The ratings
indicating ‘some concerns’ about the possible presence of bias
were primarily the result of non-reporting of key trial design fea-
tures. The probability of bias due to intervention group allocation
was rated as high for approximately 40–60% of the trials, depend-
ing on the outcome. A high rating of bias under this domain was
driven by studies where allocation to treatment group was not
random or where the authors provided no information about
the method of allocating pigs to different treatment groups, and
where there were imbalances between the treatment groups at
baseline. Across all outcomes, trials were categorized from low
to high risk of bias due to deviations from the intended interven-
tions and missing outcome data. For mortality, all studies were at
a low risk of bias from outcome measurement, because outcome
assessors were not likely to be biased in their recordings of mor-
tality regardless of whether they were blinded. In contrast, the risk
of bias related to outcome measurement in trials reporting
Fig. 1. PRISMA flow chart illustrating the flow of literature through the review process for a systematic review of the efficacy of bacterial vaccines for preventing
respiratory disease in swine.
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morbidity or lung lesions ranged from low risk to high risk,
because of the potential for knowledge of intervention status to
influence assessors’ measurement of the subjective outcome. For
bias due to selective reporting of outcomes, all trials for all out-
comes were assigned a rating of ‘some concerns’ about the pres-
ence of bias because an a priori trial protocol is needed to
judge whether a trial is at a high or low risk of bias in this domain,
and a priori protocols were not available for any trial.
Study results
Not all of the trials that measured a given outcome were included
in the NMA because some intervention arms were collapsed into
a single category, some trials did not provide a description of one
or more vaccine interventions, and some trials had zero cells that
precluded the calculation of an OR. In addition, only a small
number of trials assessed some of the outcomes, and the NMA
would be uninformative due to wide confidence intervals if
there was only a small number of contributing trials. As a result,
NMA was only conducted for the three most commonly reported
outcomes: clinical morbidity (n = 20 trials contributing to the net-
work), mortality (n = 54 trials contributing to the network), and
presence/absence of non-specific lung lesions (n = 27 trials con-
tributing to the network) (Fig. 1).
Incidence of clinical morbidity
Structure of the network
Of the 24 trials that measured clinical morbidity, three did not
describe the specific vaccine used in one or more intervention
arms and one trial had no animals with morbidity in one or
more intervention groups, and therefore a RR could not be calcu-
lated. Thus, there were 20 trials with 27 treatment comparisons that
reported a clinical morbidity outcome and contributed to the
NMA. The network of intervention comparisons for the clinical
morbidity outcome is shown in Fig. 2; the number of comparisons
for each intervention is shown in parentheses beside the interven-
tion node, and the abbreviations are defined in Table 2. Although
some vaccine-to-vaccine comparisons were present in the network,
a non-active treatment (not treated, placebo, or sham treatment)
was the most common intervention arm reported. The network
was generally sparse (small number of trials contributing to most
comparisons), and the predominance of some intervention arms
suggested a non-random distribution of intervention evaluations.
None of the trials reported any statistical adjustments for pen
effects (i.e. statistical non-independence of pigs within pens).
Although data from all intervention arms with clinical mor-
bidity outcomes informed the NMA, relative results for vaccine
efficacy are presented only for eligible vaccines with a bacterial
pathogen target and placebo controls. For the group of trials
with morbidity as an outcome, comparative results are presented
for 14 vaccines plus a non-active intervention group.
Results of individual studies and synthesis of results
RRs for all pairwise comparison for the bacterial vaccines, including
comparisons to a non-active control, are available in the
Supplementary material Table S2. Figure 3 illustrates the relative
ranking of each eligible vaccine for preventing morbidity along
with 95% credibility intervals; the mean rankings are available in
the Supplementary material Table S3. For the majority of interven-
tions, the credibility intervals were wide and overlapping; of the 14
vaccine intervention arms, six represented a single direct
comparison, six represented two comparisons, and two intervention
arms were represented by more than two comparisons. Based on
the relative ranking, Ingelvac HP-1 and Respisure/Respisure One
ranked as more efficacious than a non-active control. However,
these results were based on a small number of comparisons, and
therefore these relative rankings should be interpreted with caution.
These results are consistent with the distribution of the probability
of failure (morbidity) for each vaccine (see Supplementary material
Fig. S4), where there are no substantial differences in the probability
of failure (morbidity) between vaccine interventions.
Measures of the consistency of the direct and indirect compar-
isons for morbidity as an outcome are available in the
Supplementary material Table S4. There was no evidence of
inconsistency between the direct and indirect estimates because
the credible intervals for all comparisons included the null
value of no difference between the two values.
Mortality
Structure of the network
Of the 81 trials that measured mortality, 14 did not describe the
specific vaccine used in one or more intervention arms, eight
did not have extractable data, two applied the interventions in
sows and measured the outcome in offspring, two did not have
an intervention arm that linked to the network (i.e. was not com-
mon to an intervention arm in any other trials), and one trial had
no mortality in one or more intervention groups, and therefore a
RR could not be calculated. Thus, there were 54 trials that reported
mortality as an outcome and contributed to the NMA. None of the
trials included adjustments for pen effects. The network for all
intervention arms that included estimates of mortality is shown
in Fig. 4; the number of comparisons involving each intervention
is shown in parentheses beside the intervention node and the acro-
nyms are defined in Table 2. More intervention arms contributed
to this network compared to the morbidity outcome network. The
most common intervention arm in this network also was the non-
active treatment arm and most of the trials included comparisons
between a vaccine and a non-active treatment arm, rather than
vaccine-to-vaccine comparisons. None of the trials included in
the mortality analysis had an adjustment for pen effects.
Results of individual studies and synthesis of results
Relative results are presented only for eligible vaccines and placebo
controls. For mortality as an outcome, comparative results are pre-
sented for 28 vaccines plus a non-active intervention group.
RRs for all pairwise comparison for the bacterial vaccines,
including comparisons to a placebo, are available in the
Supplementary material Table S5. Figure 5 shows the relative
ranking of each eligible vaccine for preventing mortality, with
95% credibility intervals. The three vaccines with the highest aver-
age ranks were Ingelvac HP-1 and Respisure, which both target
M. hyopneumoniae, and Porcilis APP, which targets A. pleurop-
neumoniae. However, the results for Ingelvac HP-1 and
Respisure are each based on only one trial. The mean rankings
are available in the Supplementary material Table S6 and the dis-
tribution of the probability of failure (mortality) for each vaccine
is available in Supplementary material Fig. S5.
An evaluation of the consistency of the direct and indirect
comparisons for mortality as an outcome is available in
Supplementary material Table S7. Similar to the results for the
clinical morbidity outcome, there was no evidence of inconsist-
ency between direct and indirect estimates.
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Presence or absence of non-pathogen-specific lung lesions at
slaughter
Structure of the network
Of the 137 trials that measured lung lesions at slaughter, 39 eval-
uated lesions specific to a bacterial pathogen and 14 presented
the results using a continuous outcome scale. Thus, there were
84 trials that measured the presence or absence of non-specific
lung lesions at slaughter. Of these, 40 did not present the data
in a form that could be extracted, 12 did not provide a descrip-
tion of one or more intervention arms, four trials had zero cells
thereby precluding a calculation of a RR, and one trial did not
link to the network. Therefore, there were 27 trials that reported
the presence or absence of non-specific lung lesions at slaughter
as an outcome that contributed to the NMA. The network for all
intervention arms for which non-specific lung lesions were
reported is shown in Fig. 6; the number of comparisons involv-
ing each intervention is shown in parentheses beside the inter-
vention node and the acronyms for the vaccine labels are
defined in Table 2. Again, the most common intervention was
a non-active treatment. None of the trials included an adjust-
ment for pen effects.
Results of individual studies and synthesis of results
Results are presented for the 18 eligible vaccines that contributed
to the network plus a non-active intervention. RRs with 95% con-
fidence intervals for all pairwise comparison are available in the
Supplementary material Table S8. Figure 7 shows the relative
ranking of each eligible vaccine for preventing mortality, with
95% credibility intervals. As with clinical morbidity and mortality,
several vaccines appeared to be more efficacious at preventing
lung lesions than a non-active treatment; however, eligible vaccine
rankings were generally based on a small number of comparisons.
The mean rankings are available in the Supplementary material
Table S9. These results are consistent with the distribution of
the probability of failure (presence of lung lesions) for each vac-
cine (see Supplementary material Fig. S6).
The analysis of the consistency between the direct and indirect
comparisons for non-specific lung lesions as an outcome is shown
Fig. 2. The network of intervention arms in a network meta-analysis of the relative efficacy of bacterial vaccines to prevent morbidity in swine. The size of the circle
provides a relative indication of the number of intervention arms, the width of the line provides a relative indication of the number of direct comparisons between
interventions that were reported in the literature, and the number of arms for each intervention is shown in parentheses beside the intervention node.
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in Supplementary material Table S10. Similar to the results for
morbidity and mortality outcomes, there was no evidence of
inconsistency between the direct and indirect estimates.
Risk of bias across studies
There were a large number of possible combinations of compar-
isons between intervention arms, and so we present the risk of
bias results for only those comparisons between eligible vac-
cines. Estimates of the risk of bias across studies are presented
for the outcomes of clinical morbidity, mortality, and the pres-
ence or absence of non-specific lung lesions in Supplementary
Tables S11–13, respectively. The results focus on the risk of
bias due to the domains of randomization, blinding, impreci-
sion, and heterogeneity. For each of the three outcomes, the
contribution of studies to the RR for each comparison between
the eligible vaccines was calculated both based on the approach
to randomization and based on the approach to blinding; these
results are presented in Supplementary material Figs S7–12.
Bias due to imprecision was a major concern for many of the
comparisons under each of the three outcome headings; this
reflects the large confidence intervals surrounding the effect esti-
mates, which resulted from the small number of trials
Fig. 3. Ranking forest plot for intervention arms evaluating morbidity as an outcome for the efficacy of bacterial vaccines for swine respiratory disease. Relative
rankings and 95% credibility intervals are shown.
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contributing to each comparison. There were no comparisons
with major concerns about bias due to heterogeneity for any of
the outcomes. This result was expected based on the wide confi-
dence intervals on the RRs, which again were due to the small
number of studies contributing to any given comparison.
Across all outcomes, the risk of bias due to the randomization
process was high or unclear for a substantive component of the
evidence for many intervention comparisons. Most of the evi-
dence contributing to the treatment comparisons was derived
from studies with a high risk of bias associated with the lack of
blinding of outcome assessors and livestock caregivers.
Discussion
Summary of evidence
Despite a seemingly large number of trials evaluating one or more
bacterial vaccines for swine respiratory disease, there was an
insufficient body of evidence available from which to draw firm,
evidence-based conclusions about the relative efficacy of available
commercial vaccines. Several factors exacerbated the lack of data:
there was little replication of each specific vaccine intervention in
the existing literature with only one or two estimates contributing
to most estimates; the metrics and measurements used for out-
comes varied considerably across trials; and small sample sizes
in trials investigating rare outcomes resulted in zero cells, render-
ing it difficult to calculate effect sizes.
Limitations of the body of literature
Clinical trials are fundamental to understanding the efficacy of an
intervention. However, a single trial does not provide a definitive
answer to a clinical question, as the results of a single trial
represent only one random result from a distribution of possible
results. Even when trials are addressing identical research ques-
tions, differences in the results between trials may occur due to
subtle differences in the populations, interventions, or outcomes
Fig. 4. The network of intervention arms in a network meta-analysis of the relative efficacy of bacterial vaccines to prevent mortality in swine. The size of the circle
provides a relative indication of the number of intervention arms, the width of the line provides a relative indication of the number of direct comparisons between
interventions that were reported in the literature, and the number of arms for each intervention is shown in parentheses beside the intervention node.
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studied, or due to differences in the disease exposure experience of
the experimental animals. Thus, replication of studies is essential
to understand the true efficacy of an intervention.
In creating the network of vaccine interventions, we combined
vaccines produced by the same company for the same bacterial tar-
get, even if the dose, frequency, or route of administration differed.
This was done to increase the power of the network, although it
introduced some heterogeneity into the intervention definition.
Nonetheless, even after some vaccine interventions were combined,
the majority of intervention arms were represented in only one or
two trials. In addition, a non-active treatment arm was the most
common comparison group, meaning that most of the
Fig. 5. Ranking forest plot for intervention arms evaluating mortality as an outcome for the efficacy of bacterial vaccines for swine respiratory disease. Relative
ranking and 95% credibility intervals are shown.
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vaccine-to-vaccine comparisons depended on indirect evidence,
which is not as strong as direct evidence. The networks of interven-
tions presented for each outcome may assist researchers in identi-
fying which direct vaccine-to-vaccine or vaccine-to-placebo studies
could be undertaken in the future to help build a more robust net-
work for evaluating the relative efficacy of these vaccines.
There also was considerable variation in the methods and
metrics used to measure morbidity and lung lesions, as well as
variation in the outcomes that were reported in different trials.
When the same outcome is measured in different ways (e.g. mor-
bidity based on clinical signs versus morbidity based on antibiotic
treatment requirements), heterogeneity is introduced into the
results, thus decreasing the precision of the efficacy estimates.
Variation in the outcomes reported across trials also reduces the
power of evidence synthesis, because different outcomes (e.g. non-
specific lung lesions versus lung lesions specific to a particular
pathogen) cannot be meaningfully combined in the same MA.
One possible solution is to develop and use a core set of outcomes
for all trials addressing a given health issue, such as the prevention
of respiratory disease in swine. This approach has been used for
trials investigating several different human health care issues
(for examples of recent protocols for developing core outcome
sets, see Wuytack et al. (2018) and O’Donnell et al. (2019)).
Guidelines for developing core outcome sets have been recently
published by the Core Outcome Measures in Effectiveness
Trials (COMET) initiative (Williamson et al., 2017). Creation of
a core outcome set does not restrict researchers from reporting
other outcomes in their trial publications, but rather provides a
recommendation for a minimum set of outcomes to be included
in all trials, thus allowing trial results to be compared or synthe-
sized across studies.
The network of studies would have been considerably larger
had we included challenge trials as an eligible study design.
Challenge trials are often conducted during the development
and assessment phases of an intervention to provide proof of con-
cept for efficacy. However, they differ from trials with natural dis-
ease exposure in that the disease challenge may not be
representative of the disease exposure affecting animals in field
conditions, and challenge trials often are conducted in more con-
trolled settings than are typical in most livestock facilities
(Sargeant et al., 2014a, 2014b). Challenge trials also are more
likely to indicate beneficial treatment effects compared to natural
exposure trials investigating the same intervention(s) (Egger et al.,
1997; Wisener et al., 2014). This is partially related to publication
bias, because challenge trials tend to involve smaller numbers of
animals than natural exposure trials and studies with small sam-
ple sizes also are more likely to be published if they show statis-
tically significant results. Therefore, the published results of
challenge trials may not be representative of the true range of
results from those trials (Egger and Smith, 1998). For these rea-
sons, we did not include challenge studies in this review.
We included in the present analysis all trials that met the eli-
gibility criteria, regardless of whether or not other strategies to
prevent respiratory disease were in place. Thus, the included
trials could be evaluating whether vaccines worked as a single
preventive strategy or whether there was an added benefit
beyond other preventative measures already in place, such as
biosecurity, all-in all-out management, or prophylactic antibio-
tics. As the volume of research on vaccine efficacy grows, it
may be important to consider this difference and to clearly
report any additional disease prevention measures that affect
the animals in the trial.
Fig. 6. The network of intervention arms in a network
meta-analysis of the relative efficacy of bacterial vac-
cines to prevent non-specific lung lesions in swine.
The size of the circle provides a relative indication of
the number of intervention arms, the width of the line
provides a relative indication of the number of direct
comparisons between interventions that were reported
in the literature, and the number of arms for each inter-
vention is shown in parentheses beside the intervention
node.
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Although the pigs in all of the included studies were housed in
pens, none of the studies included an adjustment for the non-
independence of pigs within pens. This is a necessary step regard-
less of whether or not animals in different intervention groups are
comingled within pens. When non-independence or clustering
within pens is not accounted for in the analysis, the confidence
intervals will be inappropriately narrow and the P-values will be
inappropriately small. This in turn might lead researchers to over-
estimate the precision and increases the probability of a type I
error (i.e. there appears to be a significant association when one
does not exist) (Schukken et al., 2003). Statistical methods are
available to control for non-independence, and should be applied
in all studies in which animals are grouped or multiple farms are
included.
Additionally, this review included both trials in which individ-
ual pigs were allocated to each treatment group (with or without
comingling within pens), as well as those with allocation to inter-
vention occurring at the pen level. If trial pens are grouped within
barns, then it is possible that pigs in different intervention groups
are sharing the same air space. This may mean that pigs in a non-
active treatment group are afforded some protection from infec-
tion due to herd immunity, which could bias vaccine efficacy
results toward the null.
In addition to the challenge of insufficient data for meaningful
synthesis, there were also issues related to potential biases in the
trials that were included in the review. In some cases, trial reports
did not include key design features such as random allocation to
treatment groups and the blinding of study personnel and animal
caregivers to intervention status. In other instances, information
related to the key features needed to assess the potential for bias
was not provided in the trial reports, making it impossible to
assess bias risks. This is not an uncommon issue in the animal
health literature; deficiencies in reporting have been documented
in numerous studies (Wellman and O’Connor, 2007; Burns and
O’Connor, 2008; Sargeant et al., 2009a, 2009b; Brace et al.,
2010; Winder et al., 2019). Poor reporting of study design features
has been associated with exaggerated treatment effects in numer-
ous studies in both the animal and human health literature
(Moher et al., 1998; Burns and O’Connor, 2008; Sargeant et al.,
2009a, 2009b). In response to concerns about reporting deficien-
cies in livestock trials, the REFLECT statement was developed by
an expert consensus process (O’Connor et al., 2010a). The
REFLECT statement consists of a 22-item checklist to provide
guidance on the components of trials that should be reported in
publications, as well as an explanation and elaboration document
that provides additional information about each item on the
checklist. The REFLECT statement methods and elaboration pub-
lications were co-published in multiple journals (O’Connor et al.,
2010a, 2010b, 2010c, 2010d, 2010e; Sargeant et al., 2010a, 2010b)
and also are available online (http://www.reflect-statement.org/;
https://meridian.cvm.iastate.edu/). Improved reporting of trial
design, methods, and results will help readers to judge the validity of
trial results and to make meaningful comparisons across studies.
Limitations of the review
Although we attempted to conduct a comprehensive search, it is
possible that not all of the relevant existing literature was cap-
tured. We used the names of bacterial respiratory pathogens
and broad terms for vaccination, but did not include the commer-
cial names of specific vaccines, as these may vary over time and by
country; thus, we may have missed trial reports that used only a
vaccine name without mentioning that it was a respiratory patho-
gen vaccine. Additionally, our review included only English-
language articles. Therefore, the results of this review may not
be representative of the entire body of literature assessing bacterial
vaccines for respiratory disease on swine. Further, we collapsed
intervention arms and combined similar outcomes to improve
Fig. 7. Ranking forest plot for intervention arms evaluat-
ing non-specific lung lesions at slaughter as an outcome
for the efficacy of bacterial vaccines for swine respira-
tory disease. Relative ranking and 95% credibility inter-
vals are shown.
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the number of treatment and outcome replications included in the
NMA. There may have been some misclassification of the mor-
bidity outcome, in that not all trials provided information as to
whether all treated animals were treated specifically for respiratory
disease. It is possible that our decision rules for combining inter-
ventions or outcomes impacted our results. If there were any sub-
stantive differences in the treatments or outcomes that were
combined in the NMA, the differential impacts of those variations
would be obscured. However, we attempted to be transparent in
terms of how the data were manipulated for the analysis, allowing
the reader to consider whether they agree with the grouping
decisions.
Conclusions
This review identified 179 trials evaluating vaccines for bacterial
causes of respiratory disease in swine. However, because of the
variability in outcome measurements and the small number of
trials replicating each of the vaccine interventions, the compara-
tive efficacy results from the NMA had wide confidence intervals.
In many cases, the confidence intervals spanned values indicating
both appreciable benefits and appreciable harms due to the vac-
cine intervention, and so clear conclusions about the efficacy of
vaccines to manage respiratory disease in swine could not be
made. There were also deficiencies in the reporting of key design
features in many of the trials, which resulted in a high or unclear
risk of bias. The limitations for research synthesis identified by
this review were a function of the body of work rather than the
synthesis methods. The same limitation would apply for an expert
opinion or narrative review based on this body of work, although
it may not be as apparent or transparent as it occurs when system-
atic review methods are employed. Future research could use the
networks presented in this review to target gaps in vaccine trial
replication to build a more robust body of literature. Adhering
to recommendations for the reporting of livestock trials will
improve the comparability of studies and the assessment of the
potential for bias in trial results.
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